Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) Director Arthur A. Levin sold 40,000 shares of Avidity Biosciences stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $35.07, for a total transaction of $1,402,800.00. Following the completion of the transaction, the director now directly owns […]
Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) CEO Sarah Boyce sold 28,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $27.42, for a total value of $767,760.00. Following the completion of the transaction, the chief executive officer now directly […]
Shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) traded down 4.3% on Tuesday . The stock traded as low as $26.07 and last traded at $26.27. 447,285 shares were traded during mid-day trading, a decline of 60% from the average session volume of 1,124,135 shares. The stock had previously closed at $27.45. Analyst […]
Avidity Biosciences (NASDAQ:RNA – Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.02, Zacks reports. Avidity Biosciences had a negative net margin of 2,103.78% and a negative return on equity of 37.98%. The company had revenue of […]
Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has received a consensus rating of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have updated their coverage on the stock in the […]